PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.45%
Revenue growth 1.25-1.5x CRON.TO's 3.70%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
2.54%
Gross profit growth under 50% of CRON.TO's 5.61%. Michael Burry would be concerned about a severe competitive disadvantage.
-215.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.44%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-117.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-120.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-123.71%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.20%
Share reduction while CRON.TO is at 25.88%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.20%
Reduced diluted shares while CRON.TO is at 25.88%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-15.34%
Negative OCF growth while CRON.TO is at 234.45%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
3.14%
FCF growth under 50% of CRON.TO's 94.16%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
-43.07%
Negative 5Y CAGR while CRON.TO stands at 204.60%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-27.65%
Negative 3Y CAGR while CRON.TO stands at 41.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-3018.29%
Negative 10Y OCF/share CAGR while CRON.TO stands at 199.63%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
67.43%
5Y OCF/share CAGR at 50-75% of CRON.TO's 106.62%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-26.57%
Negative 3Y OCF/share CAGR while CRON.TO stands at 115.92%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-5286.33%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-248.74%
Negative 5Y net income/share CAGR while CRON.TO is 66.60%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-882.73%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
10337.78%
10Y equity/share CAGR above 1.5x CRON.TO's 1410.50%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-34.81%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-58.34%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.36%
AR growth is negative/stable vs. CRON.TO's 23.99%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
0.65%
Inventory shrinking or stable vs. CRON.TO's 21.79%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-1.65%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.34%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.77%
We’re deleveraging while CRON.TO stands at 10.68%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-42.86%
Our R&D shrinks while CRON.TO invests at 17.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.77%
We cut SG&A while CRON.TO invests at 8.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.